| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/01/2004 | US20040126359 Modulate lymphocyte activation; cell proliferation; apoptosis; signal transduction |
| 07/01/2004 | US20040126355 Antimicrobial skin preparation |
| 07/01/2004 | US20040126351 Topical composition having natural skin anti-irritant ingredient and method of use |
| 07/01/2004 | US20040126330 Nicotine-containing film preparation |
| 07/01/2004 | US20040126329 Delivery of analgesics through an inhalation route |
| 07/01/2004 | US20040126328 Arerosol; heating drug, vaporization, cooling |
| 07/01/2004 | US20040126327 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route |
| 07/01/2004 | US20040126326 Delivery of antidepressants through an inhalation route |
| 07/01/2004 | US20040126324 Mixture of ion exchange resin and drug |
| 07/01/2004 | US20040126323 Transdermal dosage form comprising an active agent and a salt and free-base form of an adverse agent |
| 07/01/2004 | DE202004007434U1 Film tablet, to carry high dosage medications, has a structured notch in one main surface to allow accurate parts to be broken off without a risk of over or under dosing |
| 07/01/2004 | DE10351663A1 Stable, accurately dosable inhalable powder medicament for treating asthma or chronic obstructive pulmonary disease, containing tiotropium, specific form of salmeterol xinafoate and auxiliary |
| 07/01/2004 | DE10261825A1 Verwendung von Hypericin und/oder dessen Derivaten zur Tumorprävention Use of hypericin and / or its derivatives for the prevention of tumor |
| 07/01/2004 | DE10261130A1 Arzneimittel enthaltend substituierte 2,5-Diaminomethyl-1H-pyrrole Medicines containing substituted 2,5-diaminomethyl-1H-pyrroles |
| 07/01/2004 | DE10259844A1 New mannopyranoside-based peptidomimetic compounds, useful for treatment or diagnosis of e.g. intestinal, autoimmune or tumor diseases, are selective alpha4, beta7-integrin antagonists |
| 07/01/2004 | DE10259407A1 New bicyclic nitrogen-containing heteroaryl-substituted amides, are inhibitors of Factor Xa and/or related serine proteases, useful as antithrombotic agents, e.g. for treating or preventing deep leg vein thrombosis |
| 07/01/2004 | DE10257949A1 Cosmetic or dermatological preparation for use on sensitive skin in treating e.g. inflammations or wounds contains thiodiglycol |
| 07/01/2004 | CA2810477A1 Oral drug delivery system |
| 07/01/2004 | CA2808592A1 A set of oligo-nucleotides against hiv infection and its application in the prevention and treatment of acquired immune deficiency syndrome |
| 07/01/2004 | CA2808584A1 A set of oligo-nucleotides against hiv infection and its application in the prevention and treatment of acquired immune deficiency syndrome |
| 07/01/2004 | CA2808190A1 A set of oligo-nucleotides against hiv infection and its application in the prevention and treatment of acquired immune deficiency syndrome |
| 07/01/2004 | CA2801155A1 Oral drug delivery system |
| 07/01/2004 | CA2779723A1 Oral drug delivery system |
| 07/01/2004 | CA2679030A1 Alpha-2-delta ligand to treat lower urinary track symptoms |
| 07/01/2004 | CA2510625A1 Crystalline forms of gatifloxacin and processes for preparation |
| 07/01/2004 | CA2510261A1 Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof |
| 07/01/2004 | CA2510223A1 Transdermal buprenorphine dosage regimen for analgesia |
| 07/01/2004 | CA2510143A1 Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors |
| 07/01/2004 | CA2510043A1 Tiotropium containing hfc solution formulations |
| 07/01/2004 | CA2510038A1 Process for the chemical stabilization of a solubilized retinoid in a solvent using a base |
| 07/01/2004 | CA2509830A1 Pharmaceutical compositions of sertaconazole for vaginal use |
| 07/01/2004 | CA2509633A1 3h-quinazolin-4-one derivatives |
| 07/01/2004 | CA2509620A1 Light-shielding agent and film-forming composition |
| 07/01/2004 | CA2509616A1 Combination therapy for the treatment of pain |
| 07/01/2004 | CA2509615A1 Gabapentin analogues for fibromyalgia and other related disorders |
| 07/01/2004 | CA2509611A1 Method of treatment for sexual dysfunction |
| 07/01/2004 | CA2509600A1 Pharmaceutical uses for alpha2delta ligands |
| 07/01/2004 | CA2509356A1 Glucose and/or fructose transporter naglt1 and its gene |
| 07/01/2004 | CA2509283A1 Steroid compounds with anti-tumor activity |
| 07/01/2004 | CA2509244A1 Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 |
| 07/01/2004 | CA2509216A1 Pharmaceutical porous particles |
| 07/01/2004 | CA2509214A1 Indolizine compounds |
| 07/01/2004 | CA2509101A1 A topical nanoparticulate spironolactone formulation |
| 07/01/2004 | CA2508855A1 Valproic acid analogues and pharmaceutical compositions thereof |
| 07/01/2004 | CA2508823A1 Method and reagents for treating or preventing atherosclerosis and diseases associated therewith |
| 07/01/2004 | CA2508780A1 Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors |
| 07/01/2004 | CA2508297A1 Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders |
| 07/01/2004 | CA2507629A1 Enantiomers of thiophene hydroxamic acid derivatives and their use as hdac inhibitors |
| 07/01/2004 | CA2507522A1 Oral drug delivery system |
| 07/01/2004 | CA2507427A1 Quaternary ammonium esters for disinfection and preservation |
| 07/01/2004 | CA2506809A1 Combinations of valsartan with cox-2 inhibitors |
| 07/01/2004 | CA2506807A1 Controlled release preparations comprising tramadol and topiramate |
| 07/01/2004 | CA2506442A1 Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
| 07/01/2004 | CA2506204A1 Novel benzopyran analogs and their use for the treatment of glaucoma |
| 07/01/2004 | CA2505788A1 Pregabalin derivatives for the treatment of fibromyalgia and other disorders |
| 07/01/2004 | CA2505406A1 Pharmaceutical compositions comprising a combination of calcitriol and a clobetasol propionate |
| 07/01/2004 | CA2503147A1 Stable topiramate formulations |
| 07/01/2004 | CA2498043A1 Preparation of submicron sized particles with polymorph control and new polymorph of itraconazole |
| 06/30/2004 | WO2004060326A1 Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis |
| 06/30/2004 | EP1433855A2 Plasmids suitable for il-2 expression |
| 06/30/2004 | EP1433786A1 Benzoxazole compound and pharmaceutical composition containing the compound |
| 06/30/2004 | EP1433783A2 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 06/30/2004 | EP1433781A1 Pyrrolidine carboxylic acid derivatives |
| 06/30/2004 | EP1433780A1 19-nor-vitamin D3 compounds with calcemic activity |
| 06/30/2004 | EP1433778A1 Use of nitriles as rotamase inhibitors |
| 06/30/2004 | EP1433482A1 Aqueous preparation containing a shark-derived chondroitin iron sulfate colloid |
| 06/30/2004 | EP1433481A1 The use of methyltestosterone for the treatment of human papilloma virus infections |
| 06/30/2004 | EP1433480A1 Medicine containing pyrimidine derivative |
| 06/30/2004 | EP1433479A1 Appetite-stimulating agents and remedies for anorexia |
| 06/30/2004 | EP1433478A1 Pharmaceutical formulae for thyroid hormones and procedures for obtaining them |
| 06/30/2004 | EP1433477A2 External skin treatment stabilized composition comprising retinol |
| 06/30/2004 | EP1432993A2 In vitro model for priocidal activity |
| 06/30/2004 | EP1432816A2 Use of active substances for the prophylaxis and/or treatment of diseases caused by cell growth disturbances and test system for discovery of said active substances |
| 06/30/2004 | EP1432799A2 Silencing of gene expression by sirna |
| 06/30/2004 | EP1432796A1 Stable episomal vectors |
| 06/30/2004 | EP1432783A1 Decontamination of surfaces contaminated with prion-infected material with gaseous oxidizing agents |
| 06/30/2004 | EP1432737A2 Human mini-antibody cytotoxic for tumor cells which express the erbb2 receptor |
| 06/30/2004 | EP1432736A2 METHODS FOR DIAGNOSING AND TREATING DISEASES AND CONDITIONS ASSOCIATED WITH PROTEIN KINASE C$g(l) |
| 06/30/2004 | EP1432734A1 Cytokine receptor |
| 06/30/2004 | EP1432724A1 Rna interference mediated inhibition of map kinase genes |
| 06/30/2004 | EP1432723A2 Modulation of the expression of genes dependent on stat-1 |
| 06/30/2004 | EP1432721A1 Process for the preparation of rebeccamycin and analogs thereof |
| 06/30/2004 | EP1432718A1 Chemical compounds |
| 06/30/2004 | EP1432715A2 Pyrimidine derivatives |
| 06/30/2004 | EP1432714A2 Chemical compounds |
| 06/30/2004 | EP1432713A2 Fused pyrimidine dhfr inhibitors as antibacterials |
| 06/30/2004 | EP1432712A1 Imidazo-pyridine derivatives for use in the treatment of herpes viral infection |
| 06/30/2004 | EP1432711A1 1,6-naphthyridine derivatives as antidiabetics |
| 06/30/2004 | EP1432710A1 1, 8-naphthyridine derivatives as antidiabetics |
| 06/30/2004 | EP1432709A1 1-glyoxlylamide indolizines for treating cancer |
| 06/30/2004 | EP1432708A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo 3,2-c]pyridine derivatives for treatment of obesity |
| 06/30/2004 | EP1432707A1 Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
| 06/30/2004 | EP1432706A2 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors |
| 06/30/2004 | EP1432705A2 Dual action antibiotics |
| 06/30/2004 | EP1432703A1 Heterocycle-carboxamide derivatives as raf kinase inhibitors |
| 06/30/2004 | EP1432702A1 Nitrogen-containing heterocyclic compounds and their use as raf inhibitors |
| 06/30/2004 | EP1432701A1 Heterocyclic compounds for use in the treatment of disorders of the urinary tract |
| 06/30/2004 | EP1432700A1 Spiro-hydantoin compounds useful as anti-inflammatory agents |
| 06/30/2004 | EP1432699A1 Pyridylfurans and pyrroles as raf kinase inhibitors |
| 06/30/2004 | EP1432698A2 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors |